FDA Budget Issues Creep Into Strategic Priorities
This article was originally published in The Pink Sheet Daily
Executive Summary
“Given the limited availability of investment capital for medical product development, early clarification of regulatory requirements is critical,” FDA says.
You may also be interested in...
FDA Gives Innovation, Harmonization Added Attention In Final Priorities Report
The agency made subtle but potentially notable changes from a draft in its final five-year strategic priorities document, released Sept. 30.
FDA Gives Innovation, Harmonization Added Attention In Final Priorities Report
Industry comments lead to subtle but notable changes; agency also makes a few deletions, additions of its own including deemphasizing cost-control projects, highlighting antibiotic development and changing the status of its facility improvements.
FDA Gives Innovation, Harmonization Added Attention In Final Priorities Report
Industry comments lead to subtle but notable changes; agency also makes a few deletions, additions of its own including deemphasizing cost-control projects, highlighting antibiotic development and changing the status of its facility improvements.